TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37255729

Group type: EXPERIMENTAL
Intervention: Physiotherapist-led 50-minute mixed exercise program, three times a week for 12 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group treatment as usual
Number of subjects: 14
Study: 37255987

Group type: EXPERIMENTAL
Intervention: Lasmiditan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37256099

Group type: EXPERIMENTAL
Intervention: High-dose tadalafil
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 37256186

Group type: EXPERIMENTAL
Intervention: Neoadjuvant Toripalimab (240mg, every 3 weeks) plus double platinum-based chemotherapy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Thyroid dysfunction (irAE)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Rash/pruritus (irAE)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Patients without irAEs
Number of subjects: 55
Study: 37256193

Group type: EXPERIMENTAL
Intervention: 0.8ng/kg endotoxin injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline placebo injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study: 37256238

Group type: EXPERIMENTAL
Intervention: Supervised high-intensity interval training (3 times weekly for 6 months)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Lifestyle as usual (control group)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Supervised high-intensity interval training
Number of subjects: 150
Study: 37256434

Group type: EXPERIMENTAL
Intervention: Manual freehand SUV assessment
Number of subjects: 14
Study: 37256536

Group type: EXPERIMENTAL
Intervention: LAMA/LABA (tiotropium/olodaterol, Respimat)
Number of subjects: 463

Group type: COMPARATOR
Intervention: TT (treatment group)
Number of subjects: 463
Study: 37256558

Group type: EXPERIMENTAL
Intervention: Eptinezumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37256578

Group type: EXPERIMENTAL
Intervention: Expedited postoperative activity instructions
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard restrictions
Number of subjects: 107
Study: 37256598

Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 4394

Group type: COMPARATOR
Intervention: Coronary Artery Bypass Graft (CABG)
Number of subjects: 4394
Study: 37256614

Group type: EXPERIMENTAL
Intervention: Circulating cardiomyocyte cfDNA measured after anthracycline therapy
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Post-anthracycline cardiomyocyte cfDNA level
Number of subjects: 71
Study: 37256623

Group type: EXPERIMENTAL
Intervention: Surgeon-palliative care comanagement
Number of subjects: 359

Group type: COMPARATOR
Intervention: Surgeon-alone management
Number of subjects: 359
Study: 37256621

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (10 days treatment)
Number of subjects: 799

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 799
Study: 37256634

Group type: EXPERIMENTAL
Intervention: Interpersonal support domains
Number of subjects: 0
Study: 37256680

Group type: EXPERIMENTAL
Intervention: Adaptive Content Tuning (ACT) mechanism applied to social network interventions (SNIs) delivering tailored organ donation-related educational content through Facebook.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard social network interventions (SNIs) without the ACT mechanism.
Number of subjects: 0
Study: 37256753

Group type: EXPERIMENTAL
Intervention: QoR-15
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: SF-8
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: QoR-15 and SF-8
Number of subjects: 135
Study: 37256861

Group type: EXPERIMENTAL
Intervention: eGFR creatinine
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: eGFR cystatin C
Number of subjects: 38

Group type: COMPARATOR
Intervention: iohexol clearance
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Length of ICU stay
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Change in creatinine-to-cystatin C ratio
Number of subjects: 38
Study: 37256863

Group type: EXPERIMENTAL
Intervention: Benznidazole (BNZ) 7.5 mg/kg/d administered in two daily doses for 60 days
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Benznidazole (BNZ) 7.5 mg/kg/d
Number of subjects: 81
Study: 37256885

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) using 100% oxygen at a pressure of 2.0-2.4 atmospheres absolute (203-243 kPa) for 90 minutes, five times per week
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Subgroup analysis based on pre-existing respiratory disease, smoking history, and applied treatment pressure
Number of subjects: 86
Study: 37256916

Group type: EXPERIMENTAL
Intervention: ALVAC-HIV alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E gp120 alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ALVAC-HIV + AIDSVAX B/E gp120
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ALVAC-HIV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (RV144 regimen)
Number of subjects: 0
Study: 37256976

Group type: EXPERIMENTAL
Intervention: Capivasertib plus fulvestrant
Number of subjects: 708

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Capivasertib plus fulvestrant (AKT pathway-altered population)
Number of subjects: 708

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant (AKT pathway-altered population)
Number of subjects: 708
Study: 37257121

Group type: EXPERIMENTAL
Intervention: DTwP-IPV-HB-PRP~T
Number of subjects: 459

Group type: COMPARATOR
Intervention: DTwP-HB-PRP~T+bOPV+IPV
Number of subjects: 459
Study: 37257143

Group type: EXPERIMENTAL
Intervention: Blinatumomab plus chemotherapy
Number of subjects: 255

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 255
Study: 37257184

Group type: EXPERIMENTAL
Intervention: Tele-Yoga intervention
Number of subjects: 0
Study: 37257193

Group type: EXPERIMENTAL
Intervention: Myeloablative conditioning (MAC) haploBMT with posttransplant cyclophosphamide (PTCy), mycophenolate mofetil, and tacrolimus.
Number of subjects: 32
Study: 37257366

Group type: EXPERIMENTAL
Intervention: Initial scoring (IS)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Secondary consensus scoring (CS)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Determination of awake epochs
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Determination of non-rapid-eye-movement stage 2 (N2) epochs
Number of subjects: 15
Study: 37257422

Group type: EXPERIMENTAL
Intervention: Standard steroid eye drops
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Standard steroid eye drops plus vasoconstrictor eye drops and cold compress
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Enhanced steroids plus vasoconstrictor eye drops and cold compress
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 90
Study: 37257563

Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate (LC) breakfast
Number of subjects: 121

Group type: COMPARATOR
Intervention: Low-Fat Control (CTL) breakfast
Number of subjects: 121
Study: 37257564

Group type: COMPARATOR
Intervention: SQ-LNS (20 g/d)
Number of subjects: 966

Group type: COMPARATOR
Intervention: Iron and folic acid until delivery, then placebo
Number of subjects: 966

Group type: COMPARATOR
Intervention: Multiple micronutrients (MMNs)
Number of subjects: 966
Study: 37257905

Group type: EXPERIMENTAL
Intervention: New race-free kidney recipient specific GFR equation
Number of subjects: 15489

Group type: COMPARATOR
Intervention: Race-free CKD-EPI 2021 equation
Number of subjects: 15489
Study: 37258077

Group type: EXPERIMENTAL
Intervention: 30 minutes of aerobic exercise
Number of subjects: 80

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 80
Study: 37258079

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seropositivity testing
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Household factors (type 2 diabetes, food stamps, lower education)
Number of subjects: 332
Study: 37258080

Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 220
Study: 37258095

Group type: EXPERIMENTAL
Intervention: Fixed dose combination (FDC) of two or more antihypertensives and a statin with or without aspirin
Number of subjects: 18162

Group type: EXPERIMENTAL
Intervention: FDC with aspirin
Number of subjects: 18162

Group type: EXPERIMENTAL
Intervention: FDC without aspirin
Number of subjects: 18162

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18162

Group type: EXPERIMENTAL
Intervention: FDC
Number of subjects: 18162

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 18162
Study: 37258299

Group type: EXPERIMENTAL
Intervention: Sleep-Disordered Breathing (SDB) severity
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Apnea-hypopnea index
Number of subjects: 122
Study: 37258525

Group type: EXPERIMENTAL
Intervention: Microbiome Enhancer Diet (MBD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Western Diet (WD)
Number of subjects: 0
Study: 37258647

Group type: EXPERIMENTAL
Intervention: Nasal mucosal biopsy and sinonasal examination
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sinonasal outcome test-22 (SNOT-22)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cough evaluation test (CET)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Correlation between SNOT-22 and CET
Number of subjects: 40
Study: 37258715

Group type: EXPERIMENTAL
Intervention: MDMA (100 mg) and LSD (100 µg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: LSD alone
Number of subjects: 24

Group type: COMPARATOR
Intervention: MDMA alone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 37259053

Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly (AOM) treatment for 6 months
Number of subjects: 396
Study: 37259081

Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF) to adopt Team-Based Care (TBC) principles for hypertension management
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 90
Study: 37259087

Group type: EXPERIMENTAL
Intervention: myPlan app (n=147)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Control (usual web-based resources; n=146)
Number of subjects: 293
Study: 37259124

Group type: COMPARATOR
Intervention: ParkinsonAKTIV intervention (online platform for guiding non-pharmacological treatment decisions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health-related quality of life and physician-assessed health status (Unified Parkinson Disease Rating Scale)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health economic evaluation using patient-reported outcomes and cost data
Number of subjects: 0
Study: 37259138

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 13
Study: 37259147

Group type: COMPARATOR
Intervention: University-based comprehensive stroke centres (UCSC)
Number of subjects: 3431

Group type: COMPARATOR
Intervention: Non university-based comprehensive stroke centres (nUCSC)
Number of subjects: 3431

Group type: COMPARATOR
Intervention: Primary stroke centres at non-university hospitals (PCS)
Number of subjects: 3431

Group type: EXPERIMENTAL
Intervention: Patients with severe stroke (NIHSS score ≥5)
Number of subjects: 3431

Group type: EXPERIMENTAL
Intervention: Patients with ischaemic stroke vs. TIA
Number of subjects: 3431

Group type: EXPERIMENTAL
Intervention: Patients younger than 60 years
Number of subjects: 3431

Group type: EXPERIMENTAL
Intervention: Echocardiography (TTE and/or TEE)
Number of subjects: 3431

Group type: EXPERIMENTAL
Intervention: Detection of AF in-hospital
Number of subjects: 3431
Study: 37259157

Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia plus usual care
Number of subjects: 135

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 135
Study: 37259190

Group type: EXPERIMENTAL
Intervention: Reactive step training (2 weeks, 6 sessions)
Number of subjects: 25
Study: 37259248

Group type: EXPERIMENTAL
Intervention: 25 g of ketone ester (KE)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo drink (EX CON)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo drink (R CON)
Number of subjects: 10
Study: 37259253

Group type: EXPERIMENTAL
Intervention: BFR group (traditional rehabilitation with a medical grade tourniquet applied to the upper arm)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-BFR group (traditional rehabilitation only)
Number of subjects: 28
Study: 37259255

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (150 min of supervised, moderate-intensity aerobic exercise per week for 24 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal exercise attendance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal exercise level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal exercise level and infant activity state
Number of subjects: 0
Study: 37259323

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine treatment
Number of subjects: 49
Study: 37259500

Group type: EXPERIMENTAL
Intervention: Female AIS patients
Number of subjects: 482

Group type: COMPARATOR
Intervention: Male AIS patients
Number of subjects: 482
Study: 37259567

Group type: EXPERIMENTAL
Intervention: Azacitidine (75 mg/m2 days 1-7) + Lenalidomide (2.5 or 5 mg days 1-21) + Donor lymphocyte infusions (0.5×10^6-1.5×10^7 cells/kg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Azacitidine + Lenalidomide + Donor lymphocyte infusions
Number of subjects: 50
Study: 37259592

Group type: EXPERIMENTAL
Intervention: Experimental occupational therapy plus intensive standard rehabilitation
Number of subjects: 92
Study: 37259605

Group type: EXPERIMENTAL
Intervention: Glycated Albumin (GA)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Glycated Hemoglobin A1c (HbA1c)
Number of subjects: 34
Study: 37259693

Group type: EXPERIMENTAL
Intervention: Apraclonidine 0.5% solution, administered as two drops to the most affected eye.
Number of subjects: 10
Study: 37259789

Group type: EXPERIMENTAL
Intervention: Intraoperative Channeling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37259807

Group type: EXPERIMENTAL
Intervention: circSCORE
Number of subjects: 149

Group type: COMPARATOR
Intervention: MCL35
Number of subjects: 149
Study: 37259859

Group type: EXPERIMENTAL
Intervention: Chronic total occlusion percutaneous coronary intervention (CTO PCI)
Number of subjects: 12928
Study: 37259861

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 369
Study: 37260074

Group type: EXPERIMENTAL
Intervention: Intravitreal anti-VEGF
Number of subjects: 1914
Study: 37260130

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (onabotA)
Number of subjects: 504
Study: 37260158

Group type: EXPERIMENTAL
Intervention: Pamiparib 60 mg orally twice daily (BID)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo orally BID
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Pamiparib 60 mg orally BID
Number of subjects: 136
Study: 37260160

Group type: EXPERIMENTAL
Intervention: Endocare (VR solution)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sham (control)
Number of subjects: 102
Study: 37260252

Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 318
Study: 37260254

Group type: EXPERIMENTAL
Intervention: Additional boost with ALVAC-HIV and AIDSVAX (group 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Additional boost with AIDSVAX alone (group 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No additional boost (group 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Additional boost
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trogocytosis
Number of subjects: 0
Study: 37260312

Group type: EXPERIMENTAL
Intervention: Medical interval (from first consultation to appropriate antibiotics administration)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Patient interval (from first signs of COSBI to the first medical consultation)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Initial hospital referral for consultation
Number of subjects: 227
Study: 37260368

Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil (FTD/TPI)
Number of subjects: 307
Study: 37261117

Group type: EXPERIMENTAL
Intervention: D-dimer/LDH/leukocytes
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: D-dimer/LDH/neutrophils
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: D-dimer/LDH/leukocytes/neutrophils
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Laboratory data (leukocytes, neutrophils, D-dimer, LDH)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Interferon alpha 2 protein
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Leukocyte inhibitory factor
Number of subjects: 93
Study: 37261364

Group type: EXPERIMENTAL
Intervention: Atazanavir 2dd300 mg
Number of subjects: 20
Study: 37261384

Group type: EXPERIMENTAL
Intervention: MINOCA females ≤70 years old
Number of subjects: 2455

Group type: COMPARATOR
Intervention: MINOCA males
Number of subjects: 2455

Group type: COMPARATOR
Intervention: MIOCA females
Number of subjects: 2455

Group type: COMPARATOR
Intervention: MIOCA males
Number of subjects: 2455
Study: 37261531

Group type: EXPERIMENTAL
Intervention: Eliapixant 25 mg
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Eliapixant 75 mg
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Eliapixant 150 mg
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study: 37261566

Group type: EXPERIMENTAL
Intervention: Psychiatric consultation and navigation program including EHR decision support tool, consultation with a child and adolescent psychiatrist, and up to 6 months of behavioral health care navigation
Number of subjects: 348
Study: 37261615

Group type: EXPERIMENTAL
Intervention: Fluorine-18-labeled SSAs
Number of subjects: 10

Group type: COMPARATOR
Intervention: Gallium-68-labeled SSAs
Number of subjects: 10
Study: 37261636

Group type: EXPERIMENTAL
Intervention: Patients with PoTS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy Controls (HCs)
Number of subjects: 30
Study: 37261654

Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy (AET)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Treatment-emergent pain interference
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor receipt
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Mastectomy
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: White race
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Treatment-emergent endocrine symptoms
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Higher stage
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Treatment-emergent physical function decline
Number of subjects: 309
Study: 37261664

Group type: EXPERIMENTAL
Intervention: Estradiol valerate 2-6 mg plus spironolactone 100-200 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: PrEP (tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg)
Number of subjects: 19
Study: 37261804

Group type: EXPERIMENTAL
Intervention: Camrelizumab (200 mg IV every 2 weeks), Apatinib (250 mg oral once daily), Temozolomide (200 mg/m2 IV once daily on days 1-5)
Number of subjects: 50
Study: 37261806

Group type: EXPERIMENTAL
Intervention: Adaptive Radiotherapy (ART)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard Intensity-Modulated Radiotherapy (IMRT)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Both arms
Number of subjects: 132
Study: 37261831

Group type: EXPERIMENTAL
Intervention: Chemotherapy (fluorouracil or capecitabine, with some receiving doublet chemotherapy or bevacizumab)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Observation-first group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Treatment-first group
Number of subjects: 24
Study: 37261839

Group type: COMPARATOR
Intervention: Low-dose atropine 0.02%
Number of subjects: 576

Group type: COMPARATOR
Intervention: Low-dose atropine 0.01%
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 576
Study: 37261885

Group type: EXPERIMENTAL
Intervention: mHealth lifestyle intervention (details not specified)
Number of subjects: 14
Study: 37261907

Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection (RCI)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone (IVMP)
Number of subjects: 37
Study: 37261916

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Baseline electroretinogram 30-Hz flicker implicit time
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Genetic subtype
Number of subjects: 765
Study: 37262038

Group type: EXPERIMENTAL
Intervention: Structured nutrition and advanced carbohydrate counting questionnaire
Number of subjects: 0
Study: 37262040

Group type: EXPERIMENTAL
Intervention: Ivermectin (IVM) administered as part of triple-drug therapy, with dosing groups of 200 μg/kg, 18 mg, and 36 mg.
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Ivermectin (IVM) administered as part of triple-drug therapy.
Number of subjects: 56
Study: 37262066

Group type: EXPERIMENTAL
Intervention: Transcutaneous CO2 monitoring using TCM4
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Transcutaneous CO2 monitoring using TCM5
Number of subjects: 100

Group type: COMPARATOR
Intervention: Arterial blood gas (ABG) measurements
Number of subjects: 100
Study: 37262130

Group type: EXPERIMENTAL
Intervention: Knowledge and attitudes toward hospice and palliative care
Number of subjects: 35
Study: 37262189

Group type: EXPERIMENTAL
Intervention: Parboiled ribe rice
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Parboiled long B rice (flora method)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Parboiled long B rice (conventional method)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: White rice cake (by-product of parboiled rice)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Brown rice cake (by-product of parboiled rice)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Different varieties of parboiled rice (ribe, white and brown long B, basmati, black, red, roma, and arborio)
Number of subjects: 10
Study: 37262194

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0